- Stéphane Bancel, Chief Executive Officer
- Stephen Hoge, M.D., President
- Juan Andres, Chief Technical Operations and Quality Officer
- Marcello Damiani, Chief Digital and Operational Excellence Officer
- Tracey Franklin, Chief Human Resources Officer
- Lori Henderson, J.D., General Counsel and Corporate Secretary
- Lorence Kim, M.D., Chief Financial Officer
- Megan Pace, Chief Corporate Affairs Officer
- Tal Zaks, M.D., Ph.D., Chief Medical Officer
Chief Executive Officer
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Stephen Hoge, M.D.
As the President of Moderna, Stephen Hoge leads our platform R&D, therapeutic area research, and pre-clinical development efforts. He joined Moderna in late 2012 from McKinsey & Company where he was a partner in the healthcare practice. Prior to McKinsey, Dr. Hoge was a resident physician in New York City.
He holds an M.D. with thesis from the University of California, San Francisco and a B.S. in neuroscience from Amherst College.
Currently, Dr. Hoge also serves on the Board of Directors of Axcella Health, Inc., a private biotechnology company.
Chief Technical Operations and Quality Officer
As Chief Technical Operations and Quality Officer, Juan Andres is responsible for the supply of product required for Moderna’s preclinical and clinical development programs, as well as scaling the CMC (chemistry, manufacturing and controls) processes across Moderna’s portfolio. Mr. Andres also will lead all CMC late-stage development and future commercialization activities.
Mr. Andres was previously the Global Head of Technical Operations (Manufacturing and Supply Chain) for over 25,000 Novartis employees across all of its divisions. In this role, he had responsibility for all of Novartis’ manufacturing sites, and related support functions and technologies worldwide, overseeing small molecules drug substance and drug product, as well as biologics drug substance, drug product and technical development. Mr. Andres’ previous roles at Novartis included Group Novartis Quality Head, Global Head of Technical Research and Development, and Global Pharmaceutical Operations Head. Prior to Novartis, Mr. Andres worked at Eli Lilly & Co. for 18 years in a variety of manufacturing, production and quality roles in the United States, Puerto Rico, UK and Spain, most recently serving as Vice President, Pharmaceutical Manufacturing.
Mr. Andres holds a Master degree in Pharmacy from Alcala de Henares University in Madrid and completed an advanced development program at the London Business School.
Chief Digital and Operational Excellence Officer
As Chief Digital and Operational Excellence Officer, Marcello Damiani brings a wealth of experience from both Tech companies and Life Science companies and a true passion for making Digital a reality. He has 20 years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and in the U.S.
Prior to joining Moderna, Mr. Damiani was instrumental in conceiving and building creative IT solutions to help solve business challenges, first at Motorola and then at bioMérieux. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes. He is known for his ability to transform a company’s Information flow, and ultimately improving the product and the company’s processes through digitization.
Mr. Damiani possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and an international Executive MBA through TRIUM, an alliance of three of the world’s top universities: the London School of Economics, New York University’s Stern Business School, and the HEC School of Management in Paris.
Chief Human Resources Officer
As Chief Human Resources Officer, Tracey Frankin leads Moderna’s talent and organizational strategy.
Ms. Franklin joins Moderna following 15 years at Merck & Co., Inc. where she most recently led Merck’s global talent strategy as Vice President, HR Chief Talent and Strategy Officer and served on Merck’s HR Leadership Team. In this role, Ms. Franklin was responsible for leading the vision, development and execution of the company’s Talent and Workforce Strategy with a focus on evolving the organizational culture and talent for the future. Ms. Franklin’s previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck’s global footprint. She was based in Switzerland, the U.K. and the U.S.
Ms. Franklin holds a bachelor’s in communication arts and sciences from Pennsylvania State University and a master’s in industrial and organizational psychology from Fairleigh Dickinson University.
Lori Henderson, J.D.
General Counsel and Corporate Secretary
As general counsel and corporate secretary, Lori Henderson leads Moderna’s legal, governance and corporate compliance efforts. She comes to Moderna with nearly 30 years as a corporate attorney in both law firm and general counsel roles guiding both global public and private companies.
Ms. Henderson has deep business development, regulatory and governance experience, and has worked extensively with executive leadership teams both in public and private companies. She came to Moderna from Albany Molecular Research (AMRI), a Waltham-based pharmaceutical contract research and manufacturing organization, where she was Senior Vice President, General Counsel, Corporate Secretary and Head of Business Development. There she led global legal and business development functions, and had extensive involvement with pharmaceutical and licensing partners, the acquisition and integration of multiple companies, and ultimately the sale of the company to private equity in late 2017.
Prior to AMRI, she was General Counsel, Corporate Secretary and Chief Administrative Officer at Rand Worldwide, a technology sales and services organization and prior to that, General Counsel, Corporate Secretary and Chief Administrative Officer of Moldflow Corporation (which was sold to Autodesk). She started her career in the corporate practice of the Boston law firm Goodwin Procter.
Ms. Henderson received her Juris Doctorate from The George Washington University Law School and her B.A. from Gordon College.
Lorence Kim, M.D.
Chief Financial Officer
Lorence Kim joined Moderna from Goldman Sachs where he was a managing director and co-head of the U.S. biotechnology investment banking effort. He joined Goldman Sachs in 1999 as a summer associate and was named managing director in 2008. As a member of the healthcare investment banking group for nearly 14 years, Dr. Kim’s responsibilities included corporate finance and mergers and acquisitions (M&A) for the pharmaceutical and biotechnology industries, with several billion in equity and equity linked financings, and more than $55 billion in M&A transactions.
Prior to joining Goldman Sachs, Dr. Kim worked in various medical research and consulting positions concurrent with his graduate studies. Dr. Kim graduated from Harvard University, magna cum laude and Phi Beta Kappa with an A.B. in biochemical sciences in 1995. He also earned an MBA in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000 and an M.D. from the University of Pennsylvania’s School of Medicine in 2000.
Dr. Kim is currently a member of the Board of Directors of Seres Therapeutics.
Chief Corporate Affairs Officer
As chief corporate affairs officer, Megan Pace is responsible for Moderna’s communications and public affairs activities, including corporate and internal communications, government affairs, community relations and patient advocacy. She joins Moderna after nearly 20 years working with and for leading biotechnology and pharmaceutical companies.
Prior to Moderna, Ms. Pace was senior vice president, strategic operations and PKR program executive at Agios, where she served as a member of the executive team. She was also the senior vice president of corporate communications at Vertex, during the period when the company evolved from a research and development organization and successfully launched its first two commercial products. In this role, she was on the company’s leadership team and was responsible for global corporate, product and employee communications and patient advocacy. Ms. Pace was also senior director, Public Affairs at Genentech, Inc. where she was responsible for product communications and public affairs. She also worked on the communications and government affairs teams at Eli Lilly and Company as well as at Porter Novelli, a global public relations firm. She began her career working on political campaigns in her home state of Florida and in a Congressional office in Washington DC.
Ms. Pace holds a B.A. from the College of Charleston. She is a board member of the Boomer Esiason Foundation and the Make-a-Wish Foundation of Massachusetts and Rhode Island.
Tal Zaks, M.D., Ph.D.
Chief Medical Officer
As Chief Medical Officer, Tal Zaks oversees clinical development and regulatory affairs across Moderna. Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization.
Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is associate professor of medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers.
Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.
Dr. Zaks serves on the Board of Directors of Adaptimmune Therapeutics plc.